b'<?xml version="1.0" ?>\n<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">\n<pmc-articleset><article dtd-version="1.3" xml:lang="en" article-type="research-article">\n  <?properties open_access?>\n  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">\n    <restricted-by>pmc</restricted-by>\n  </processing-meta>\n  <front>\n    <journal-meta>\n      <journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id>\n      <journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id>\n      <journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>\n      <journal-title-group>\n        <journal-title>Frontiers in Endocrinology</journal-title>\n      </journal-title-group>\n      <issn pub-type="epub">1664-2392</issn>\n      <publisher>\n        <publisher-name>Frontiers Media S.A.</publisher-name>\n      </publisher>\n    </journal-meta>\n    <article-meta>\n      <article-id pub-id-type="pmid">34621245</article-id>\n      <article-id pub-id-type="pmc">8491582</article-id>\n      <article-id pub-id-type="doi">10.3389/fendo.2021.743155</article-id>\n      <article-categories>\n        <subj-group subj-group-type="heading">\n          <subject>Endocrinology</subject>\n          <subj-group>\n            <subject>Original Research</subject>\n          </subj-group>\n        </subj-group>\n      </article-categories>\n      <title-group>\n        <article-title>Identification of mRNA Prognostic Markers for TGCT by Integration of Co-Expression and CeRNA Network</article-title>\n      </title-group>\n      <contrib-group>\n        <contrib contrib-type="author">\n          <name>\n            <surname>Zhu</surname>\n            <given-names>Fang</given-names>\n          </name>\n          <xref rid="aff1" ref-type="aff">\n<sup>1</sup>\n</xref>\n          <xref rid="fn003" ref-type="author-notes">\n<sup>&#x2020;</sup>\n</xref>\n        </contrib>\n        <contrib contrib-type="author">\n          <name>\n            <surname>Liu</surname>\n            <given-names>Zhizhong</given-names>\n          </name>\n          <xref rid="aff1" ref-type="aff">\n<sup>1</sup>\n</xref>\n          <xref rid="aff2" ref-type="aff">\n<sup>2</sup>\n</xref>\n          <xref rid="fn003" ref-type="author-notes">\n<sup>&#x2020;</sup>\n</xref>\n        </contrib>\n        <contrib contrib-type="author">\n          <name>\n            <surname>Zhou</surname>\n            <given-names>Qianyin</given-names>\n          </name>\n          <xref rid="aff1" ref-type="aff">\n<sup>1</sup>\n</xref>\n          <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1475438"/>\n        </contrib>\n        <contrib contrib-type="author">\n          <name>\n            <surname>Fan</surname>\n            <given-names>Jingyu</given-names>\n          </name>\n          <xref rid="aff3" ref-type="aff">\n<sup>3</sup>\n</xref>\n          <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1475784"/>\n        </contrib>\n        <contrib contrib-type="author">\n          <name>\n            <surname>Zhou</surname>\n            <given-names>Dai</given-names>\n          </name>\n          <xref rid="aff1" ref-type="aff">\n<sup>1</sup>\n</xref>\n          <xref rid="aff4" ref-type="aff">\n<sup>4</sup>\n</xref>\n          <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1299299"/>\n        </contrib>\n        <contrib contrib-type="author">\n          <name>\n            <surname>Xing</surname>\n            <given-names>Liu</given-names>\n          </name>\n          <xref rid="aff4" ref-type="aff">\n<sup>4</sup>\n</xref>\n          <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1475797"/>\n        </contrib>\n        <contrib contrib-type="author" corresp="yes">\n          <name>\n            <surname>Bo</surname>\n            <given-names>Hao</given-names>\n          </name>\n          <xref rid="aff1" ref-type="aff">\n<sup>1</sup>\n</xref>\n          <xref rid="aff4" ref-type="aff">\n<sup>4</sup>\n</xref>\n          <xref rid="fn001" ref-type="author-notes">\n<sup>*</sup>\n</xref>\n          <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1475757"/>\n        </contrib>\n        <contrib contrib-type="author" corresp="yes">\n          <name>\n            <surname>Tang</surname>\n            <given-names>Le</given-names>\n          </name>\n          <xref rid="aff5" ref-type="aff">\n<sup>5</sup>\n</xref>\n          <xref rid="fn001" ref-type="author-notes">\n<sup>*</sup>\n</xref>\n          <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1475798"/>\n        </contrib>\n        <contrib contrib-type="author" corresp="yes">\n          <name>\n            <surname>Fan</surname>\n            <given-names>Liqing</given-names>\n          </name>\n          <xref rid="aff1" ref-type="aff">\n<sup>1</sup>\n</xref>\n          <xref rid="aff4" ref-type="aff">\n<sup>4</sup>\n</xref>\n          <xref rid="fn001" ref-type="author-notes">\n<sup>*</sup>\n</xref>\n          <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1410985"/>\n        </contrib>\n      </contrib-group>\n      <aff id="aff1"><sup>1</sup><institution>National Health Commission Key Laboratory of Human Stem Cell and Reproductive Engineering, Institute of Reproductive and Stem Cell Engineering, Central South University</institution>, <addr-line>Changsha</addr-line>, <country>China</country></aff>\n      <aff id="aff2"><sup>2</sup><institution>Hunan Cancer Hospital, Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine of Central South University</institution>, <addr-line>Changsha</addr-line>, <country>China</country></aff>\n      <aff id="aff3"><sup>3</sup><institution>Department of Chemistry and Biochemistry, University of South Carolina</institution>, <addr-line>Columbia, SC</addr-line>, <country>United States</country></aff>\n      <aff id="aff4"><sup>4</sup><institution>Clinical Research Center for Reproduction and Genetics in Hunan Province, Reproductive and Genetic Hospital of China International Trust and Investment Corporation (CITIC) Xiangya</institution>, <addr-line>Changsha</addr-line>, <country>China</country></aff>\n      <aff id="aff5"><sup>5</sup><institution>Reproductive Medicine Center, Maternal and Child Health Care Hospital of Hunan Province</institution>, <addr-line>Changsha</addr-line>, <country>China</country></aff>\n      <author-notes>\n        <fn fn-type="edited-by">\n          <p>Edited by: Graciela Susana Diaz-Torga, Consejo Nacional de Investigaciones Cient&#xED;ficas y T&#xE9;cnicas (CONICET), Argentina</p>\n        </fn>\n        <fn fn-type="edited-by">\n          <p>Reviewed by: Norbert Nass, St&#xE4;dtische Klinikum Dessau, Germany; Rossella Cannarella, University of Catania, Italy</p>\n        </fn>\n        <corresp id="fn001">*Correspondence: Hao Bo, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:166501030@csu.edu.cn">166501030@csu.edu.cn</email>; Le Tang, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:starkstang@hotmail.com">starkstang@hotmail.com</email>; Liqing Fan, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:liqingfan@csu.edu.cn">liqingfan@csu.edu.cn</email>\n</corresp>\n        <fn fn-type="equal" id="fn003">\n          <p>&#x2020;These authors have contributed equally to this work</p>\n        </fn>\n        <fn fn-type="other" id="fn002">\n          <p>This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology</p>\n        </fn>\n      </author-notes>\n      <pub-date pub-type="epub">\n        <day>21</day>\n        <month>9</month>\n        <year>2021</year>\n      </pub-date>\n      <pub-date pub-type="collection">\n        <year>2021</year>\n      </pub-date>\n      <volume>12</volume>\n      <elocation-id>743155</elocation-id>\n      <history>\n        <date date-type="received">\n          <day>17</day>\n          <month>7</month>\n          <year>2021</year>\n        </date>\n        <date date-type="accepted">\n          <day>31</day>\n          <month>8</month>\n          <year>2021</year>\n        </date>\n      </history>\n      <permissions>\n        <copyright-statement>Copyright &#xA9; 2021 Zhu, Liu, Zhou, Fan, Zhou, Xing, Bo, Tang and Fan</copyright-statement>\n        <copyright-year>2021</copyright-year>\n        <copyright-holder>Zhu, Liu, Zhou, Fan, Zhou, Xing, Bo, Tang and Fan</copyright-holder>\n        <license>\n          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>\n          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>\n        </license>\n      </permissions>\n      <abstract>\n        <p>Testicular germ cell tumor (TGCT) is the most common malignant tumor in young men and is associated with poor prognosis. We assessed the RNA expression profiles of 13 TGCT tissues and 4 adjacent normal tissues by transcriptome sequencing to identify novel prognostic biomarkers. We detected several differentially expressed mRNAs in TGCT that were functionally annotated by GO and KEGG enrichment analyses to tumorigenesis-related processes such as immunity and chemotherapeutic resistance. An mRNA-lncRNA-miRNA regulatory network was constructed using RNA-Seq data and public databases, and integrated with TCGA database to develop a prediction model for metastasis and recurrence. Finally, GRK4, PCYT2 and RGSL1 were identified as predictive markers of survival and therapeutic response. In conclusion, we found several potential predictors for TGCT prognosis and immunotherapeutic response by ceRNA network analysis.</p>\n      </abstract>\n      <kwd-group>\n        <kwd>testicular germ cell tumors</kwd>\n        <kwd>prognostic markers</kwd>\n        <kwd>risk factor</kwd>\n        <kwd>immune cell infiltration</kwd>\n        <kwd>chemotherapy resistance</kwd>\n        <kwd>competitive endogenous RNAs network</kwd>\n      </kwd-group>\n      <counts>\n        <fig-count count="6"/>\n        <table-count count="1"/>\n        <equation-count count="1"/>\n        <ref-count count="37"/>\n        <page-count count="11"/>\n        <word-count count="4073"/>\n      </counts>\n    </article-meta>\n  </front>\n  <body>\n    <sec sec-type="intro" id="s1">\n      <title>Introduction</title>\n      <p>Testicular germ cell tumors (TGCTs) are prevalent among males between the ages of 20 and 35 years, and the incidence rates are increasing globally. Approximately 90-95% of testicular cancers are TGCTs that are derived from the germ cell lineage (<xref rid="B1" ref-type="bibr">1</xref>). Histologically, TGCTs are classified into the seminomas (SEM) and non-seminomas (non-SEM), of which the latter can be sub-divided into teratomas, yolk sac tumors, choriocarcinomas, embryonal carcinomas (ECs) and mixed tumors (<xref rid="B2" ref-type="bibr">2</xref>). Non-SEM has a high risk of metastasis and recurrence, and the ECs in particular that originate from the malignant testicular stem cells are the most aggressive TGCT subtype due to vascular invasion (<xref rid="B3" ref-type="bibr">3</xref>&#x2013;<xref rid="B5" ref-type="bibr">5</xref>). However, the mechanisms underlying the poor prognosis of TGCTs are poorly understood.</p>\n      <p>Although TGCT is generally sensitive to cisplatin-based chemotherapy, approximately 20% of the patients are unresponsive to the treatment and have significantly worse prognoses or a high risk of recurrence, along with complications such as peripheral neuropathy, hormonal disturbances, sexual dysfunction, infertility, cognitive impairment and psychosocial effects (<xref rid="B6" ref-type="bibr">6</xref>&#x2013;<xref rid="B9" ref-type="bibr">9</xref>). Despite the familial nature of TGCTs, the driver genes for tumorigenesis or metastasis have not been identified so far that may be potentially targeted for therapy (<xref rid="B10" ref-type="bibr">10</xref>). Currently, most TGCT-related deaths can be attributed to metastasis and cisplatin resistance (<xref rid="B11" ref-type="bibr">11</xref>). Therefore, it is crucial to identify novel biomarkers of TGCTs to improve early diagnosis and relapse-free survival (RFS).</p>\n      <p>Recent studies have shown that in addition to mRNAs, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are involved in the pathogenesis of TGCTs (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Competing endogenous RNA (ceRNA) networks play a vital role in the regulation of oncogenic pathways (<xref rid="B14" ref-type="bibr">14</xref>). In this study, we identified multiple dysregulated RNAs in TGCTs relative to adjacent normal tissues by transcriptome sequencing. The differentially expressed mRNAs (DEmRNAs) were associated with immune cell infiltration during TGCTs progression. We constructed a ceRNA network for TGCTs based on these dysregulated mRNAs and lncRNAs, and a model for predicting RFS and immunotherapeutic responses by integrating the ceRNAs network and clinical data from public databases. These findings provide new insights into the molecular basis of TGCTs pathogenesis.</p>\n    </sec>\n    <sec sec-type="materials|methods" id="s2">\n      <title>Materials and Methods</title>\n      <sec id="s2_1">\n        <title>Clinical Specimens</title>\n        <p>Thirteen TGCT tissue samples (11 from SEM and 2 from non-SEM patients with predominantly malignant embryonal carcinoma) and 4 para-carcinoma tissues were obtained from the Department of Urology, the Affiliated Cancer Hospital of Xiangya School of Medicine of Central South University (<xref rid="T1" ref-type="table"><bold>Table&#xA0;1</bold></xref>). Fresh tissues were collected and snap frozen in liquid nitrogen. The study was approved by the Ethics Committee, and informed consent was obtained from each patient.</p>\n        <table-wrap position="float" id="T1">\n          <label>Table&#xA0;1</label>\n          <caption>\n            <p>Clinical case information of 17 testicular tissues in our sequencing.</p>\n          </caption>\n          <table frame="hsides" rules="groups">\n            <thead>\n              <tr>\n                <th valign="top" align="left" rowspan="1" colspan="1">Sample name</th>\n                <th valign="top" align="center" rowspan="1" colspan="1">Age</th>\n                <th valign="top" align="center" rowspan="1" colspan="1">Left /right</th>\n                <th valign="top" align="center" rowspan="1" colspan="1">Pathological type</th>\n                <th valign="top" align="center" rowspan="1" colspan="1">Ki67 positive rate</th>\n                <th valign="top" align="center" rowspan="1" colspan="1">The broken end of spermatic cord is involved or not</th>\n              </tr>\n            </thead>\n            <tbody>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-3</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">35</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Left</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">70%</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-4</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">44</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Right</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">60%</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-5</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">28</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Right</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">60%</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-6</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">27</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Right</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">60%</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-8</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">32</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Left</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">40%</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-2</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">58</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Left</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-9</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">33</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Right</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-10</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">31</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Right</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">80%</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-12</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">44</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Right</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">80%</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-13</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">42</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Right</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">60%</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">SEM-14</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">52</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Left</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Seminoma</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">35%</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">Non-SEM-2</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">45</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Left</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Embryonic tumor</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">Non-SEM-3</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">47</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Left</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Embryonic tumor</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">80%</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Not involved</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">Non-tumor-1</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">44</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Right</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">para-carcinoma tissue</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">&#x2013;</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">Non-tumor -2</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">45</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Left</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">para-carcinoma tissue</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">&#x2013;</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">Non-tumor -3</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">28</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Right</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">para-carcinoma tissue</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">&#x2013;</td>\n              </tr>\n              <tr>\n                <td valign="top" align="left" rowspan="1" colspan="1">Non-tumor -4</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">32</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">Left</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">para-carcinoma tissue</td>\n                <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>\n                <td valign="top" align="left" rowspan="1" colspan="1">&#x2013;</td>\n              </tr>\n            </tbody>\n          </table>\n        </table-wrap>\n      </sec>\n      <sec id="s2_2">\n        <title>RNA-Sequencing</title>\n        <p>Total RNA was extracted from tissue samples using Trizol reagent (Thermo, USA), and 1&#xB5;L per sample was used to determine the concentration using a NanoDrop 1000 spectrophotometer. After removing rRNAs (Ribo-Zero Gold rRNA Removal Kit, MRZG12324, Illumina), the remaining mRNAs and ncRNAs were purified using Agencourt RNA Clean XP Beads. The enriched mRNA and ncRNA fragments were cut into shorter sequences using a fragmentation buffer and reverse-transcribed using the Transcriptor First-strand cDNA synthesis Kit (Roche, USA). The cDNA fragments were purified to repair the ends add poly (A) and ligate the Illumina sequencing joints (QiaQuick PCR extraction kit). The second-strand cDNA was digested with uracil-N-glucanase, and amplified by PCR. The Sensitivity DNA assay Kit (Agilent Technologies) was used to analyze the quality of the library. Finally, ABI StepOnePlus Real-Time PCR System (Life Technologies) was used to quantify and pool the sequences, and the DNA sequenced on the Illumina HiSeqTM 4000 platform (Gene Denovo, Guangzhou, China).</p>\n      </sec>\n      <sec id="s2_3">\n        <title>Bioinformatics Analysis</title>\n        <p>The differentially expressed mRNAs between the two groups were screened using the edgeR software with FDR (false discovery rate) &lt; 0.01 and log2FC (fold change) &gt;1 as the thresholds for significant differences. The DEmRNAs were functionally annotated by gene ontology (GO) using the R software ClusterProfile package, and KEGG pathways using the Metascape software (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://metascape.org/gp/index.html#/main/step1">http://metascape.org/gp/index.html#/main/step1</uri>) (<xref rid="B15" ref-type="bibr">15</xref>).</p>\n      </sec>\n      <sec id="s2_4">\n        <title>Construction of the lncRNA-miRNA-mRNA Network</title>\n        <p>The DElncRNAs and DEmRNAs between the non-tumor and SEM, non-tumor and non-SEM, and non-tumor and non-SEM+SEM groups were identified using the edgeR software as described above. The common DElncRNAs and DEmRNAs among the three comparison groups were screened, and those with Spearman correlation coefficient r2&gt;0.9999 and p&lt;0.001 were selected for network construction. The target miRNAs of the lncRNA-mRNA interaction pairs were predicted using the R software miRNAtap package, TargetScan (<xref rid="B16" ref-type="bibr">16</xref>) and Miranda (<xref rid="B17" ref-type="bibr">17</xref>). The miRNAs obtained from all three programs were used to construct the lncRNA-miRNA-mRNA network, which was visualized using Cytoscape_v3.8.0.</p>\n      </sec>\n      <sec id="s2_5">\n        <title>Public Database Data Mining</title>\n        <p>The DEmRNAs were validated using the GEPIA2 database (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://gepia2.cancer-pku.cn/#index">http://gepia2.cancer-pku.cn/#index</uri>) (<xref rid="B18" ref-type="bibr">18</xref>). The RFS of the different groups (total cases 134) were plotted using the Kaplan-Meier Plotter (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://kmplot.com/analysis/index.php?p=background">http://kmplot.com/analysis/index.php?p=background</uri>), and compared in terms of P values and hazard ratios (HR) with 95% confidence intervals (CI) by the Log-rank test and univariate Cox proportional hazard regression (<xref rid="B19" ref-type="bibr">19</xref>).</p>\n      </sec>\n      <sec id="s2_6">\n        <title>Risk Factor Analysis</title>\n        <p>RNA-sequencing data (level 3) of 134 tumors and corresponding clinical information were obtained from The Cancer Genome Atlas (TCGA) dataset (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.gov/">https://www.cancer.gov/</uri>). The predictive accuracy and risk score of genes were compared by TimeRoc analysis. The minimum absolute shrinkage and selection operator (Lasso) regression algorithm was used for feature selection with 10-fold cross-validation using the R software package GLMnet. All statistical analyses were performed using R software (R Foundation for Statistical Computing, 2020) version V4.0.3. P &lt;0.05 was considered statistically significant.</p>\n      </sec>\n      <sec id="s2_7">\n        <title>Gene Set Variation Analysis</title>\n        <p>The genomic gene set analysis in TGCT was used the Gene Set Cancer Analysis (GSCA) (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bioinfo.life.hust.edu.cn/GSCA/#/">http://bioinfo.life.hust.edu.cn/GSCA/#/</uri>), which is an integrated database for genomic and immunogenomic gene set cancer analysis (<xref rid="B20" ref-type="bibr">20</xref>). Immunogenomic analysis was performed by ImmuCellAI (Immune Cell Abundance Identifier) algorithm with 24 immunes cells (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bioinfo.life.hust.edu.cn/ImmuCellAI#!/">http://bioinfo.life.hust.edu.cn/ImmuCellAI#!/</uri>) (<xref rid="B21" ref-type="bibr">21</xref>). P &lt;0.05 was considered statistically significant.</p>\n      </sec>\n    </sec>\n    <sec sec-type="results" id="s3">\n      <title>Results</title>\n      <sec id="s3_1">\n        <title>Identification of Differentially Expressed mRNAs in TGCT</title>\n        <p>A total of 11,469 mRNAs were differentially expressed between the non-tumor and non-SEM samples, of which 3,894 were up-regulated and 7,575 were down-regulated in the latter (<xref rid="f1" ref-type="fig"><bold>Figures&#xA0;1A, D</bold></xref>). Furthermore, there were 21,506 DEmRNAs in SEM relative to the non-tumor samples, of which 5974 were up-regulated and 15,632 were down-regulated (<xref rid="f1" ref-type="fig"><bold>Figures&#xA0;1B, D</bold></xref>). Finally, the SEM and non-SEM tumors exhibited 20,197 DEmRNAs, including 5,468 up-regulated and 14,729 down-regulated mRNAs compared to the non-tumor samples (<xref rid="f1" ref-type="fig"><bold>Figures&#xA0;1C, D</bold></xref>). The expression levels of the randomly selected ADAM19, DNMT3L, BRCC3, ZMIZ1, BRAP, DCAF5, FBF1 and OPTN were verified using the GEPIA2 database (<xref rid="f1" ref-type="fig"><bold>Figure&#xA0;1E</bold></xref>).</p>\n        <fig position="float" id="f1">\n          <label>Figure&#xA0;1</label>\n          <caption>\n            <p>Identification of DEmRNAs across different groups. <bold>(A-C)</bold>. Volcano plots showing the DEmRNAs between <bold>(A)</bold> non-tumor <italic>vs</italic> non-SEM, <bold>(B)</bold> non-tumor <italic>vs</italic> SEM, and <bold>(C)</bold> non-tumor <italic>vs</italic> SEM and non-SEM with |Log2FC|&gt;1 and FDR &lt;0.01. <bold>(D)</bold> Histogram showing the DEmRNAs between groups. <bold>(E)</bold> The validation of randomly selected DEmRNAs in the GEPIA database with |Log2FC|&gt;1 and p &lt;0.01 as the cut-off values. *Difference was statistically significant.</p>\n          </caption>\n          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fendo-12-743155-g001" position="float"/>\n        </fig>\n      </sec>\n      <sec id="s3_2">\n        <title>Expression Pattern of Top 100 mRNAs in TGCT</title>\n        <p>To determine the contribution of DEmRNAs to TGCT, we analyzed the top 100 mRNAs with high expression levels in the non-tumor (vs SEM + non-SEM), SEM (vs non-tumor + non-SEM), and non-SEM (vs non-tumor + SEM) samples (<xref rid="f2" ref-type="fig"><bold>Figure&#xA0;2A</bold></xref>). The highly expressed genes in the non-tumor samples were enriched in the GO terms such as &#x201C;structural constituent of ribosome&#x201D;, &#x201C;structural molecule activity&#x201D; and &#x201C;nucleoside-triphosphatase activity&#x201D; (<xref rid="f2" ref-type="fig"><bold>Figure&#xA0;2B</bold></xref>), and the &#x201C;Tight junction&#x201D;, &#x201C;Gap junction&#x201D; and &#x201C;Apoptosis&#x201D; pathways (<xref rid="f2" ref-type="fig"><bold>Figure&#xA0;2E</bold></xref>). In the non-SEM samples, the significantly enriched GO terms were &#x201C;molecular function&#x201D;, &#x201C;MHC protein complex binding&#x201D; and &#x201C;translation factor activity, RNA binding&#x201D; (<xref rid="f2" ref-type="fig"><bold>Figure&#xA0;2C</bold></xref>), whereas the main KEGG pathways were enriched in immune-related signaling pathways, such as &#x201C;B cell receptor signaling pathway&#x201D;, &#x201C;Antigen processing and presentation&#x201D; and &#x201C;intestinal immune network for IgA production&#x201D; (<xref rid="f2" ref-type="fig"><bold>Figure&#xA0;2F</bold></xref>). The highly expressed genes in SEM showed significant enrichment in &#x201C;MHC protein complex binding&#x201D; &#x201C;structural constituent of ribosome&#x201D; and &#x201C;molecular function&#x201D; (<xref rid="f2" ref-type="fig"><bold>Figure&#xA0;2D</bold></xref>), and the immune-related signaling pathways, such as &#x201C;Antigen processing and presentation&#x201D;, &#x201C;intestinal immune network for IgA production&#x201D; and &#x201C;Th17 cell differentiation&#x201D; (<xref rid="f2" ref-type="fig"><bold>Figure&#xA0;2G</bold></xref>). Furthermore, the top 100 highly expressed mRNAs in all groups were associated with multiple transcription factors, including SMARCA5 and SMARCC1, which were overexpressed in all three groups (<xref rid="f2" ref-type="fig"><bold>Figure&#xA0;2H</bold></xref>).</p>\n        <fig position="float" id="f2">\n          <label>Figure&#xA0;2</label>\n          <caption>\n            <p>Intergroup-specific expression and functional enrichment analysis of mRNAs. <bold>(A)</bold> The heatmap of top 100 highly expressed mRNAs in the non-tumor, SEM and non-SEM samples. <bold>(B&#x2013;G)</bold>. The top 20 GO terms and KEGG pathways in non-tumor <bold>(B, E)</bold>, SEM <bold>(C, F)</bold>, and non-SEM <bold>(D, G)</bold> groups. <bold>(H)</bold> Bubble chart of putative transcription factors of the top 100 mRNAs in three groups.</p>\n          </caption>\n          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fendo-12-743155-g002" position="float"/>\n        </fig>\n      </sec>\n      <sec id="s3_3">\n        <title>Enrichment Analysis of Common DEmRNAs</title>\n        <p>As shown in <xref rid="f3" ref-type="fig"><bold>Figure&#xA0;3A</bold></xref>, there were many down-regulated mRNAs in SEM and non-SEM samples compared to the controls (<xref rid="f3" ref-type="fig"><bold>Figure&#xA0;3A</bold></xref>). Specifically, 3047 mRNAs were up-regulated and 7,883 mRNAs were downregulated in the SEM and total TGCT (SEM + non-SEM) samples relative to the non-tumor controls (<xref rid="f3" ref-type="fig"><bold>Figures&#xA0;3B, C</bold></xref>). The non-SEM and combined TGCT samples showed upregulation of 196 mRNAs and downregulation of 88 mRNAs compared to the non-tumor group. Four upregulated and 18 downregulated mRNAs were common to both SEM and non-SEM groups compared to the non-tumor control (<xref rid="f3" ref-type="fig"><bold>Figures&#xA0;3B, C</bold></xref>). A pairwise comparison of all groups revealed that 2,091 upregulated mRNAs and 6,270 downregulated mRNAs were common. In addition, 1,603 and 1,191 mRNAs were respectively upregulated and downregulated only in the non-SEM group relative to the non-tumor group, whereas 732 upregulated and 1,461 downregulated mRNAs were specific to the non-tumor-vs-SEM comparison, and 134 upregulated and 488 downregulated mRNAs were only detected when comparing non-tumor samples to all TGCT samples (<xref rid="f3" ref-type="fig"><bold>Figures&#xA0;3B, C</bold></xref>). GO analysis revealed that the DEmRNAs common to all three groups were enriched in &#x201C;cell motility&#x201D;, &#x201C;movement of cell or subcellular component&#x201D; and &#x201C;cell cycle&#x201D; (<xref rid="f3" ref-type="fig"><bold>Figure&#xA0;3D</bold></xref>), and the top 20 pathways were &#x201C;cell adhesion molecules&#x201D;, &#x201C;adherence junction&#x201D; and &#x201C;Tight junction&#x201D; (<xref rid="f3" ref-type="fig"><bold>Figure&#xA0;3E</bold></xref>). Furthermore, the signaling pathways significantly associated with the top 100 common DEmRNAs included &#x201C;apoptosis signaling pathway&#x201D;, &#x201C;positive regulation of cellular component movement&#x201D;, &#x201C;leukocyte activation involved in immune&#x201D; and &#x201C;cytokine signaling in immune system&#x201D;, and were interconnected (<xref rid="f3" ref-type="fig"><bold>Figure&#xA0;3F</bold></xref>). The protein-protein interaction (PPI) network of the top 100 common DEmRNAs revealed 3,098 connections (<xref rid="f3" ref-type="fig"><bold>Figure&#xA0;3G</bold></xref>).</p>\n        <fig position="float" id="f3">\n          <label>Figure&#xA0;3</label>\n          <caption>\n            <p>Enrichment analysis of common DEmRNAs. <bold>(A)</bold> Heat map showing hierarchical clustering of common DEmRNAs in the non-tumor, SEM and non-SEM groups. <bold>(B, C)</bold> Upset plots showing the distribution of <bold>(B)</bold> upregulated and <bold>(C)</bold> downregulated mRNAs for the indicated pairs. <bold>(D, E)</bold> Bar graph showing the top 20 enriched GO and KEGG pathways associated with DEmRNAs common to all three pairs. <bold>(F)</bold> The interactive network of the enriched pathways. Different colors represent different biological processes. <bold>(G)</bold> The protein-protein interaction network (PPI) of the top 100 common DEmRNAs. Color intensity is indicative of the number of connections.</p>\n          </caption>\n          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fendo-12-743155-g003" position="float"/>\n        </fig>\n      </sec>\n      <sec id="s3_4">\n        <title>Construction and Analysis of the lncRNA-miRNA-mRNA Network</title>\n        <p>A total of 2,924 DElncRNAs and 4,842 DEmRNAs were common to the non-tumor vs SEM, non-tumor vs non-SEM+SEM, and non-tumor vs non-SEM comparisons (<xref rid="f4" ref-type="fig"><bold>Figures&#xA0;4A, B</bold></xref>). The correlated mRNA-lncRNA pairs were screened with R2 &gt; 0.9999 and p &lt; 0.001 as the criteria. Nine lncRNAs were identified, including SPATA42, AL450226.1, TCONS_00053325, DPYD-AS2, ELW67898.1, DIAPH1-AS1, Z97205.2, ISPD-AS1 and TCONS_00022110. The nine mRNAs were FAM71E2, HEPACAM2, RGSL1, DPYD-AS2, ZPBP2, DYNLRB2, PCYT2, BANF2, and GRK4. The regulatory miRNAs of the candidate mRNAs and lncRNAs were predicted by the R software miRNAtap package, TargetScan (<xref rid="B16" ref-type="bibr">16</xref>), and Miranda (<xref rid="B17" ref-type="bibr">17</xref>). We identified 8 lncRNA&#x2013;miRNA&#x2013;mRNA regulatory networks that included 9 lncRNAs nodes, 9 mRNAs nodes, and 82 miRNAs nodes with 166 possible interactions (<xref rid="f4" ref-type="fig"><bold>Figure&#xA0;4C</bold></xref>). The DEmRNAs common to non-tumor vs non-SEM and non-tumor vs SEM pairs were associated with &#x201C;movement of cell or subcellular component&#x201D;, &#x201C;reproduction&#x201D; and &#x201C;cell motility&#x201D; both in the groups of (<xref rid="f4" ref-type="fig"><bold>Figures&#xA0;4D, E</bold></xref>), whereas &#x201C;male gamete generation&#x201D;, &#x201C;cell differentiation&#x201D; and &#x201C;reproduction progress&#x201D; were the functions enriched in the DEmRNAs between non-tumor vs non-SEM + SEM (<xref rid="f4" ref-type="fig"><bold>Figure&#xA0;4F</bold></xref>). The top 20 enriched pathways among the DEmRNAs between non-tumor vs non-SEM groups were &#x201C;focal adhesion&#x201D; and &#x201C;cell adhesion molecules&#x201D; (<xref rid="f4" ref-type="fig"><bold>Figure&#xA0;4G</bold></xref>), that for non-tumor vs SEM were &#x201C;biosynthesis of secondary metabolism&#x201D;, &#x201C;steroid hormone biosynthesis&#x201D; and &#x201C;cell adhesion molecules&#x201D; (<xref rid="f4" ref-type="fig"><bold>Figure&#xA0;4H</bold></xref>), and &#x201C;cell adhesion molecules&#x201D; and &#x201C;metabolic pathway&#x201D; were enriched for non-tumor <italic>vs</italic> non-SEM + SEM (<xref rid="f4" ref-type="fig"><bold>Figure&#xA0;4I</bold></xref>).</p>\n        <fig position="float" id="f4">\n          <label>Figure&#xA0;4</label>\n          <caption>\n            <p>The lncRNA-miRNA-mRNA ceRNA network in TGCT. <bold>(A, B)</bold> Wayne diagrams of DElncRNAs <bold>(A)</bold> and DEmRNAs <bold>(B)</bold> in three comparison groups, with |log2FC|&gt;2, FDR&lt;0.01 as the thresholds. <bold>(C)</bold> The lncRNA&#x2013;miRNA&#x2013;mRNA network consisting of 9 lncRNAs (blue squares), 82 miRNAs (yellow triangles) and 9 mRNAs (rose-red circles) with 166 possible interactions. <bold>(D&#x2013;I)</bold> Enrichment analysis of the DEmRNAs in <bold>(D, G)</bold> non-tumor <italic>vs</italic> non-SEM, <bold>(E, H)</bold> non-tumor <italic>vs</italic> SEM, and <bold>(F, I)</bold> non-tumor <italic>vs</italic> SEM + non-SEM. The top 20 enriched GO terms and pathways are shown.</p>\n          </caption>\n          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fendo-12-743155-g004" position="float"/>\n        </fig>\n      </sec>\n      <sec id="s3_5">\n        <title>Evaluation of Clinical Outcomes</title>\n        <p>To explore the clinical value of the nine mRNAs (see above) in TGCTs, we obtained the raw RNA-Seq data (Level 3) of 134 TGCTs and the corresponding clinical information from TCGA dataset (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.gov/">https://www.cancer.gov/</uri>) (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table&#xA0;1</bold></xref>). A polygenic risk score (PRS) was then calculated based on the correlation between the expression levels of the nine mRNAs and prognosis using the LASSO cox regression analysis (<xref rid="f5" ref-type="fig"><bold>Figures&#xA0;5A, B</bold></xref>). Accordingly, the patients were divided into the high-risk and low-risk groups (<xref rid="f5" ref-type="fig"><bold>Figure&#xA0;5C</bold></xref>, top). Overexpression of GRK4, PCYT2 and RGSL1 was associated with increased mortality rates (<xref rid="f5" ref-type="fig"><bold>Figure&#xA0;5C</bold></xref>, middle) and a higher risk score (<xref rid="f5" ref-type="fig"><bold>Figure&#xA0;5C</bold></xref>, bottom). The prognostic index was calculated as follows:</p>\n        <disp-formula>\n<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1" display="block" overflow="scroll"><mml:mrow><mml:mtext>Risk</mml:mtext><mml:mi>&#xA0;</mml:mi><mml:mtext>score</mml:mtext><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1.841</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>*</mml:mo><mml:mtext>RGSL</mml:mtext><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>0.1582</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>*</mml:mo><mml:mtext>PCYT</mml:mtext><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>0.3161</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>*</mml:mo><mml:mi>GRK</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math>\n</disp-formula>\n        <fig position="float" id="f5">\n          <label>Figure&#xA0;5</label>\n          <caption>\n            <p>Development of the prognostic index based on ceRNA-related genes. <bold>(A)</bold> The coefficient of the selected feature is shown by the lambda parameter, with the value of the independent variable lambda on the horizontal axis and the coefficient of the independent variable on the vertical axis. <bold>(B)</bold> The relationship between partial likelihood deviation and log (&#x3BB;) was plotted using the Lasso Cox regression model. <bold>(C)</bold> Risk score curve showing survival of patients and expression profiles of the three prognostic genes in low- and high-risk groups. <bold>(D)</bold> Kaplan-Meier curve showing the association between patient survival and the three-gene signature. Median survival duration (years) corresponds to a 50% survival rate. The ROC curve and AUC of the risk model at different times. <bold>(E&#x2013;G)</bold> Survival of patients stratified based on GRK4, PCYT2, and RGSL1 expression.</p>\n          </caption>\n          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fendo-12-743155-g005" position="float"/>\n        </fig>\n        <p>KM survival analysis also confirmed that the high expression level of this gene set portended poor prognosis (log-rank p=0.0404, HR=2.077, <xref rid="f5" ref-type="fig"><bold>Figure&#xA0;5D</bold></xref>). Furthermore, the area under the time-dependent ROC curve of the gene set was greater than 0.5, indicating good predictive power (<xref rid="f5" ref-type="fig"><bold>Figure&#xA0;5D</bold></xref>). To further establish the prognostic value of GRK4, PCYT2 and RGSL1, we analyzed the correlation between their expression levels with RFS using Kaplan-Meier Plotter. PCTY2 (P=0.049, <xref rid="f5" ref-type="fig"><bold>Figure&#xA0;5F</bold></xref>) expression level showed a significant negative correlation with RFS, while that of GRK4 (P=0.12, <xref rid="f5" ref-type="fig"><bold>Figure&#xA0;5E</bold></xref>) and RGSL1 (P=0.064) were negatively correlated with RFS without statistical significance (<xref rid="f5" ref-type="fig"><bold>Figures&#xA0;5F, G</bold></xref>).</p>\n      </sec>\n      <sec id="s3_6">\n        <title>GSCA of GRK4, PCYT2, and RGSL1</title>\n        <p>The potential therapeutic relevance of GRK4, PCYT2 and RGSL1 was evaluated by GSCA (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bioinfo.life.hust.edu.cn/GSCA/#/">http://bioinfo.life.hust.edu.cn/GSCA/#/</uri>) (<xref rid="B20" ref-type="bibr">20</xref>) and Spearman correlation analysis. As shown in <xref rid="f6" ref-type="fig"><bold>Figure&#xA0;6A</bold></xref>, the expression levels of this gene set in TGCT showed a significant negative correlation with DNA damage, androgen receptor (AR), estrogen receptor (ER) and other pathways, and positive correlation with RASMAPK, TSCmTOR and other pathways (<xref rid="f6" ref-type="fig"><bold>Figure&#xA0;6A</bold></xref>). Furthermore, the gene set was also negatively correlated with the infiltration of immune cells such as Cytotoxic, TFH, B cell, CD4_T and CD8_T, and positively with Monocyte, Th2 and Macrophage (<xref rid="f6" ref-type="fig"><bold>Figure&#xA0;6B</bold></xref>, <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Tables&#xA0;2, 3</bold></xref>).</p>\n        <fig position="float" id="f6">\n          <label>Figure&#xA0;6</label>\n          <caption>\n            <p>The correlation of GRK4, PCYT2 and RGSL1 with cancer-related pathways, immune cell infiltration and GDSC. <bold>(A)</bold> Association between GSVA score and cancer-related pathways in TGCT. <bold>(B)</bold> Correlation between immune cell infiltrates and GSVA enrichment score in the selected cancers. <bold>(C)</bold> Correlation between gene expression and GDSC drug sensitivity. *P-value &lt; 0.05; <sup>#</sup>FDR &lt; 0.05.</p>\n          </caption>\n          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fendo-12-743155-g006" position="float"/>\n        </fig>\n        <p>Finally, we analyzed the correlation between drug sensitivity of cancer cell lines in GDSC (Genomics of Drug Sensitivity in Cancer), and the GRK4, PCYT2 and RGSL1 expression levels (<xref rid="B22" ref-type="bibr">22</xref>). GRK4 was correlated with the target drug 17-AAG and increased sensitivity to RDEA119, PD-0325901, CX5461, Trametinib and Selumetinib. PCYT2 showed a significant positive correlation with sensitivity to targeted drugs such as CX-5461, PI-103 (PI3K and mTOR inhibitors) and MPS-1-IN-1 (<xref rid="f6" ref-type="fig"><bold>Figure&#xA0;6C</bold></xref>).</p>\n      </sec>\n    </sec>\n    <sec sec-type="discussion" id="s4">\n      <title>Discussion</title>\n      <p>Although previous studies have identified the hereditary nature of TGCT with an estimated 37&#x2013;49% familial cases (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>), the only moderate penetrance gene is GHEK2 whose pathogenic variants have been associated with the risk of TGCT (<xref rid="B25" ref-type="bibr">25</xref>). The testis expresses the largest number of genes of any mammalian organ (<xref rid="B26" ref-type="bibr">26</xref>), especially high numbers of genes predominantly expressed (<xref rid="B27" ref-type="bibr">27</xref>). In our study, it also had numerous DEmRNAs in TGCTs. We&#xA0;identified several dysregulated mRNAs in TGCT tissues, which are likely involved in tumor development and progression. The&#xA0;upregulated mRNAs were functionally annotated to immunomodulation, cell migration and invasion, indicating a correlation between infiltration of immune cells and TGCT metastasis. The dynamics of the immune microenvironment in the scoring model based on stroma and immune cell infiltration are essential factors predicting cancer prognosis and chemotherapy response (<xref rid="B28" ref-type="bibr">28</xref>). Tumor-infiltrating immune cells are the primary immune signatures closely related to the clinical outcomes of immunotherapies (<xref rid="B29" ref-type="bibr">29</xref>). Therefore, we explored the influence of immune cells on the efficacy of immunotherapy and the clinical progression of patients with TGCT. GRK4, PCYT2 and RGSL1 were negatively correlated with the infiltration of Cytotoxic, TFH, B cell, CD4_T and CD8_T populations, and positively with that of Monocyte, Th2 and Macrophage. Recently, a study also reported that advanced TGCT is associated with a decrease in T cells and NK cells, and increased infiltration of Tregs, neutrophils, mast cells and macrophages (<xref rid="B30" ref-type="bibr">30</xref>). Furthermore, chimeric antigen receptor T (CAR-T) cells also showed anti-tumor activity against metastatic EC xenografts in a mouse model (<xref rid="B31" ref-type="bibr">31</xref>). Our results showed that upregulated mRNAs in TGCTs are likely involved in immunomodulation and immune cell infiltration, and thus promising therapeutic targets.</p>\n      <p>Numerous studies have shown that lncRNAs can compete with other RNAs to bind miRNAs, and function as ceRNAs to regulate the expression of target mRNAs (<xref rid="B32" ref-type="bibr">32</xref>). CeRNAs are repeatedly dysregulated in cancer, and involved in tumor initiation and progression (<xref rid="B14" ref-type="bibr">14</xref>). We constructed a lncRNA-miRNA-mRNA ceRNA regulatory network with the TGCT DEmRNAs and DElncRNAs and identified HEPACAM1 (TCONS_00185248) as one of the hub genes. As other studies have shown, hepatocyte cell adhesion molecules 1 and 2 (HEPACAM1 and 2) are members of the immunoglobulin family, and inhibit cell cycle progression in breast cancer via p53, p21 and p27 signaling (<xref rid="B33" ref-type="bibr">33</xref>). In addition, the nine mRNAs of the ceRNA regulatory networks included GRK4, PCYT2 and RGSL1, which showed prognostic relevance and was associated with cancer-related pathways such as DNA Damage, AR, ER, RASMAPK, and TSC-mTOR. A meta-analysis also showed that a relative reduction in androgens compared to the general population increases the risk of TGCT (<xref rid="B34" ref-type="bibr">34</xref>). Other studies have reported that the TSC1/2-mTOR pathway regulates the function of diverse immune cells, along with cell growth and metabolism (<xref rid="B35" ref-type="bibr">35</xref>&#x2013;<xref rid="B37" ref-type="bibr">37</xref>). In our study, the expression level of the gene set was correlated with the infiltration of various immune cells and therefore may regulate the immune responses to TGCT via the TSC1/2-mTOR pathway. Furthermore, GRK4 and PCYT2 were correlated with the sensitivity to multiple chemotherapeutic drugs, and PCYT2 showed a significant negative correlation with RFS in TGCT patients. Thus, GRK4, PCYT2 and RGSL1 are reliable prognostic markers and potential therapeutic targets for TGCTs.</p>\n      <p>We constructed a ceRNA network for TGCT based on the DEmRNAs and DElncRNAs for the first time, and identified markers involved in TGCT prognosis and chemotherapy resistance, which can help select the optimum clinical regimen. However, there are some limitations in our study that ought to be considered. First, our conclusions are only based on bioinformatics analysis and other methods, and further experimental verification is needed. Second, our sequencing data lacks the expression information of miRNAs, since the sample is not enough to detect the level of miRNAs. Third, patients were enrolled from only one hospital, the possible influence of regional and ethnic factors cannot be eliminated. In addition, the sample size in this study was relatively small. Finally, the involvement of GRK4, PCYT2 and RGSL1 in cancer-related pathways and drug susceptibility needs further experimental validation. In summary, our findings provide new insights into the pathogenesis of TGCT and identify GRK4, PCYT2 and RGSL1 as key prognostic markers and therapeutic targets.</p>\n    </sec>\n    <sec id="s5">\n      <title>Conclusion</title>\n      <p>We identified several dysregulated mRNAs in TGCT that are related to immunomodulation, cell migration and invasion. In addition, GRK4, PCYT2 and RGSL1A are potential TGCT-specific biomarkers that can predict RFS, tumor immunity and chemotherapeutic resistance.</p>\n    </sec>\n    <sec sec-type="data-availability" id="s6">\n      <title>Data Availability Statement</title>\n      <p>Publicly available datasets were analyzed in this study. This data can be found here: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga">https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga</uri>.</p>\n    </sec>\n    <sec sec-type="ethics-statement" id="s7">\n      <title>Ethics Statement</title>\n      <p>The studies involving human participants were reviewed and approved by Hunan Cancer Hospital, Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine of Central South University. The patients/participants provided their written informed consent to participate in this study.</p>\n    </sec>\n    <sec sec-type="author-contributions" id="s8">\n      <title>Author Contributions</title>\n      <p>HB, LT, and LF conceived and planned the experiments. FZ, DZ, and ZL collected clinical samples. HB, FZ, and ZL analyzed and interpreted the data. FZ and HB drafted the manuscript. HB, JF, and LT proofed the manuscript. LF revised and confirmed the final manuscript. All authors contributed to the article and approved the submitted version.</p>\n    </sec>\n    <sec sec-type="funding-information" id="s9">\n      <title>Funding</title>\n      <p>This research was funded by the National Key Research and Development Program of China (Nos. 2016YFC1000600), Changsha Municipal Natural Science Foundation (Nos. kq2014033), Hunan Provincial Grant for Innovative Province Construction (Nos. 2019SK4012), and the Fundamental Research Funds for the Central Universities of Central South University (Nos. 160171016).</p>\n    </sec>\n    <sec sec-type="COI-statement" id="s10">\n      <title>Conflict of Interest</title>\n      <p>Authors DZ, LX, HB and LF were employed by the company China International Trust and Investment Corporation (CITIC).</p>\n      <p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>\n    </sec>\n    <sec sec-type="disclaimer" id="s11">\n      <title>Publisher&#x2019;s Note</title>\n      <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>\n    </sec>\n  </body>\n  <back>\n    <sec sec-type="supplementary-material" id="s12">\n      <title>Supplementary Material</title>\n      <p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fendo.2021.743155/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fendo.2021.743155/full#supplementary-material</ext-link>\n</p>\n      <supplementary-material id="SM1" position="float" content-type="local-data">\n        <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_1.xlsx">\n          <caption>\n            <p>Click here for additional data file.</p>\n          </caption>\n        </media>\n      </supplementary-material>\n      <supplementary-material id="SM2" position="float" content-type="local-data">\n        <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_2.xlsx">\n          <caption>\n            <p>Click here for additional data file.</p>\n          </caption>\n        </media>\n      </supplementary-material>\n      <supplementary-material id="SM3" position="float" content-type="local-data">\n        <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_3.xlsx">\n          <caption>\n            <p>Click here for additional data file.</p>\n          </caption>\n        </media>\n      </supplementary-material>\n    </sec>\n    <ref-list>\n      <title>References</title>\n      <ref id="B1">\n        <label>1</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Fazal</surname><given-names>Z</given-names></name><name><surname>Freemantle</surname><given-names>S</given-names></name><name><surname>Spinella</surname><given-names>M</given-names></name></person-group>. <article-title>Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors</article-title>. <source>Cancers</source> (<year>2021</year>) <volume>13</volume>:<fpage>1506</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.3390/cancers13071506</pub-id>\n<pub-id pub-id-type="pmid">33805941</pub-id></mixed-citation>\n      </ref>\n      <ref id="B2">\n        <label>2</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>SR</given-names></name><name><surname>Delahunt</surname><given-names>B</given-names></name><name><surname>Magi-Galluzzi</surname><given-names>C</given-names></name><name><surname>Algaba</surname><given-names>F</given-names></name><name><surname>Egevad</surname><given-names>L</given-names></name><name><surname>Ulbright</surname><given-names>TM</given-names></name><etal/></person-group>. <article-title>The World Health Organization 2016 Classification of Testicular Germ Cell Tumours: A Review and Update From the International Society of Urological Pathology Testis Consultation Panel</article-title>. <source>Histopathology</source> (<year>2017</year>) <volume>70</volume>:<page-range>335&#x2013;46</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1111/his.13102</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B3">\n        <label>3</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moul</surname><given-names>JW</given-names></name><name><surname>McCarthy</surname><given-names>WF</given-names></name><name><surname>Fernandez</surname><given-names>EB</given-names></name><name><surname>Sesterhenn</surname><given-names>IA</given-names></name></person-group>. <article-title>Percentage of Embryonal Carcinoma and of Vascular Invasion Predicts Pathological Stage in Clinical Stage I Nonseminomatous Testicular Cancer</article-title>. <source>Cancer Res</source> (<year>1994</year>) <volume>54</volume>:<page-range>362&#x2013;4</page-range>.</mixed-citation>\n      </ref>\n      <ref id="B4">\n        <label>4</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ondrus</surname><given-names>D</given-names></name><name><surname>Matoska</surname><given-names>J</given-names></name><name><surname>Belan</surname><given-names>V</given-names></name><name><surname>Kausitz</surname><given-names>J</given-names></name><name><surname>Goncalves</surname><given-names>F</given-names></name><name><surname>Hornak</surname><given-names>M</given-names></name></person-group>. <article-title>Prognostic Factors in Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: Rationale for Different Risk-Adapted Treatment</article-title>. <source>Eur Urol</source> (<year>1998</year>) <volume>33</volume>:<page-range>562&#x2013;6</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1159/000019656</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B5">\n        <label>5</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pont</surname><given-names>J</given-names></name><name><surname>Holtl</surname><given-names>W</given-names></name><name><surname>Kosak</surname><given-names>D</given-names></name><name><surname>Machacek</surname><given-names>E</given-names></name><name><surname>Kienzer</surname><given-names>H</given-names></name><name><surname>Julcher</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Risk-Adapted Treatment Choice in Stage I Nonseminomatous Testicular Germ Cell Cancer by Regarding Vascular Invasion in the Primary Tumor: A Prospective Trial</article-title>. <source>J Clin Oncol: Off J Am Soc Clin Oncol</source> (<year>1990</year>) <volume>8</volume>:<fpage>16</fpage>&#x2013;<lpage>20</lpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1200/jco.1990.8.1.16</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B6">\n        <label>6</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caggiano</surname><given-names>C</given-names></name><name><surname>Cavallo</surname><given-names>F</given-names></name><name><surname>Giannattasio</surname><given-names>T</given-names></name><name><surname>Cappelletti</surname><given-names>G</given-names></name><name><surname>Rossi</surname><given-names>P</given-names></name><name><surname>Grimaldi</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Testicular Germ Cell Tumors Acquire Cisplatin Resistance by Rebalancing the Usage of DNA Repair Pathways</article-title>. <source>Cancers</source> (<year>2021</year>) <volume>13</volume>:<elocation-id>787</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3390/cancers13040787</pub-id>\n<pub-id pub-id-type="pmid">33668653</pub-id></mixed-citation>\n      </ref>\n      <ref id="B7">\n        <label>7</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chovanec</surname><given-names>M</given-names></name><name><surname>Abu Zaid</surname><given-names>M</given-names></name><name><surname>Hanna</surname><given-names>N</given-names></name><name><surname>El-Kouri</surname><given-names>N</given-names></name><name><surname>Einhorn</surname><given-names>LH</given-names></name><name><surname>Albany</surname><given-names>C</given-names></name></person-group>. <article-title>Long-Term Toxicity of Cisplatin in Germ-Cell Tumor Survivors</article-title>. <source>Ann Oncol: Off J Eur Soc Med Oncol</source> (<year>2017</year>) <volume>28</volume>:<page-range>2670&#x2013;9</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/annonc/mdx360</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B8">\n        <label>8</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chovanec</surname><given-names>M</given-names></name><name><surname>Lauritsen</surname><given-names>J</given-names></name><name><surname>Bandak</surname><given-names>M</given-names></name><name><surname>Oing</surname><given-names>C</given-names></name><name><surname>Kier</surname><given-names>GG</given-names></name><name><surname>Kreiberg</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Late Adverse Effects and Quality of Life in Survivors of Testicular Germ Cell Tumour</article-title>. <source>Nat Rev Urol</source> (<year>2021</year>) <volume>18</volume>:<page-range>227&#x2013;45</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/s41585-021-00440-w</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B9">\n        <label>9</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>C</given-names></name><name><surname>Dinh</surname><given-names>P</given-names><suffix>Jr.</suffix></name><name><surname>Ardeshir-Rouhani-Fard</surname><given-names>S</given-names></name><name><surname>Schaffer</surname><given-names>K</given-names></name><name><surname>Fossa</surname><given-names>SD</given-names></name><name><surname>Travis</surname><given-names>LB</given-names></name></person-group>. <article-title>Toxicities Associated With Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors</article-title>. <source>Adv Urol</source> (<year>2018</year>) <volume>2018</volume>:<elocation-id>8671832</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1155/2018/8671832</pub-id>\n<pub-id pub-id-type="pmid">29670654</pub-id></mixed-citation>\n      </ref>\n      <ref id="B10">\n        <label>10</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobo</surname><given-names>J</given-names></name><name><surname>Gillis</surname><given-names>A</given-names></name><name><surname>Jer&#xF3;nimo</surname><given-names>C</given-names></name><name><surname>Henrique</surname><given-names>R</given-names></name><name><surname>Looijenga</surname><given-names>L</given-names></name></person-group>. <article-title>Human Germ Cell Tumors Are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic</article-title>. <source>Int J Mol Sci</source> (<year>2019</year>) <volume>20</volume>:<fpage>258</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.3390/ijms20020258</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B11">\n        <label>11</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobo</surname><given-names>J</given-names></name><name><surname>Const&#xE2;ncio</surname><given-names>V</given-names></name><name><surname>Leite-Silva</surname><given-names>P</given-names></name><name><surname>Guimar&#xE3;es</surname><given-names>R</given-names></name><name><surname>Cantante</surname><given-names>M</given-names></name><name><surname>Braga</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Differential Methylation EPIC Analysis Discloses Cisplatin-Resistance Related Hypermethylation and Tumor-Specific Heterogeneity Within Matched Primary and Metastatic Testicular Germ Cell Tumor Patient Tissue Samples</article-title>. <source>Clin Epigenet</source> (<year>2021</year>) <volume>13</volume>:<fpage>70</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1186/s13148-021-01048-y</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B12">\n        <label>12</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>MK</given-names></name><name><surname>Furu</surname><given-names>K</given-names></name><name><surname>Evensen</surname><given-names>HF</given-names></name><name><surname>Haugen</surname><given-names>OP</given-names></name><name><surname>Haugen</surname><given-names>TB</given-names></name></person-group>. <article-title>Knockdown of SPRY4 and SPRY4-IT1 Inhibits Cell Growth and Phosphorylation of Akt in Human Testicular Germ Cell Tumours</article-title>. <source>Sci Rep</source> (<year>2018</year>) <volume>8</volume>:<fpage>2462</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/s41598-018-20846-8</pub-id>\n<pub-id pub-id-type="pmid">29410498</pub-id></mixed-citation>\n      </ref>\n      <ref id="B13">\n        <label>13</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morup</surname><given-names>N</given-names></name><name><surname>Rajpert-De Meyts</surname><given-names>E</given-names></name><name><surname>Juul</surname><given-names>A</given-names></name><name><surname>Daugaard</surname><given-names>G</given-names></name><name><surname>Almstrup</surname><given-names>K</given-names></name></person-group>. <article-title>Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors During Therapy and Follow-Up-A Copenhagen Experience</article-title>. <source>Cancers</source> (<year>2020</year>) <volume>12</volume>:<elocation-id>759</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3390/cancers12030759</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B14">\n        <label>14</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Pang</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>The Functional Characterization of Epigenetically Related lncRNAs Involved in Dysregulated CeRNA-CeRNA Networks Across Eight Cancer Types</article-title>. <source>Front Cell Dev Biol</source> (<year>2021</year>) <volume>9</volume>:<elocation-id>649755</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3389/fcell.2021.649755</pub-id>\n<pub-id pub-id-type="pmid">34222227</pub-id></mixed-citation>\n      </ref>\n      <ref id="B15">\n        <label>15</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Pache</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Khodabakhshi</surname><given-names>AH</given-names></name><name><surname>Tanaseichuk</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets</article-title>. <source>Nat Commun</source> (<year>2019</year>) <volume>10</volume>:<fpage>1523</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id>\n<pub-id pub-id-type="pmid">30944313</pub-id></mixed-citation>\n      </ref>\n      <ref id="B16">\n        <label>16</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>V</given-names></name><name><surname>Bell</surname><given-names>GW</given-names></name><name><surname>Nam</surname><given-names>J-W</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group>. <article-title>Predicting Effective microRNA Target Sites in Mammalian mRNAs</article-title>. <source>Elife</source> (<year>2015</year>) <volume>4</volume>:<fpage>e05005</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.7554/eLife.05005</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B17">\n        <label>17</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquinelli</surname><given-names>AE</given-names></name></person-group>. <article-title>MicroRNAs and Their Targets: Recognition, Regulation and an Emerging Reciprocal Relationship</article-title>. <source>Nat Rev Genet</source> (<year>2012</year>) <volume>13</volume>:<page-range>271&#x2013;82</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/nrg3162</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B18">\n        <label>18</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group>. <article-title>GEPIA2: An Enhanced Web Server for Large-Scale Expression Profiling and Interactive Analysis</article-title>. <source>Nucleic Acids Res</source> (<year>2019</year>) <volume>47</volume>:<page-range>W556&#x2013;60</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/nar/gkz430</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B19">\n        <label>19</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>&#xC1;.</given-names></name><name><surname>Munk&#xE1;csy</surname><given-names>G</given-names></name><name><surname>Gy&#x151;rffy</surname><given-names>B</given-names></name></person-group>. <article-title>Pancancer Survival Analysis of Cancer Hallmark Genes</article-title>. <source>Sci Rep</source> (<year>2021</year>) <volume>11</volume>:<fpage>6047</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/s41598-021-84787-5</pub-id>\n<pub-id pub-id-type="pmid">33723286</pub-id></mixed-citation>\n      </ref>\n      <ref id="B20">\n        <label>20</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>F</given-names></name><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>A</given-names></name></person-group>. <article-title>GSCALite: A Web Server for Gene Set Cancer Analysis</article-title>. <source>Bioinf (Oxford England)</source> (<year>2018</year>) <volume>34</volume>:<page-range>3771&#x2013;2</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/bioinformatics/bty411</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B21">\n        <label>21</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>YR</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Lei</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>GY</given-names></name><name><surname>Wang</surname><given-names>HX</given-names></name><etal/></person-group>. <article-title>ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and Its Application in Cancer Immunotherapy</article-title>. <source>Adv Sci</source> (<year>2020</year>) <volume>7</volume>:<elocation-id>1902880</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1002/advs.201902880</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B22">\n        <label>22</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WJ</given-names></name><name><surname>Soares</surname><given-names>J</given-names></name><name><surname>Greninger</surname><given-names>P</given-names></name><name><surname>Edelman</surname><given-names>EJ</given-names></name><name><surname>Lightfoot</surname><given-names>H</given-names></name><name><surname>Forbes</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Genomics of Drug Sensitivity in Cancer (GDSC): A Resource for Therapeutic Biomarker Discovery in Cancer Cells</article-title>. <source>Nucleic Acids Res</source> (<year>2013</year>) <volume>41</volume>:<page-range>D955&#x2013;61</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/nar/gks1111</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B23">\n        <label>23</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litchfield</surname><given-names>K</given-names></name><name><surname>Thomsen</surname><given-names>H</given-names></name><name><surname>Mitchell</surname><given-names>JS</given-names></name><name><surname>Sundquist</surname><given-names>J</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name><name><surname>Hemminki</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Quantifying the Heritability of Testicular Germ Cell Tumour Using Both Population-Based and Genomic Approaches</article-title>. <source>Sci Rep</source> (<year>2015</year>) <volume>5</volume>:<elocation-id>13889</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/srep13889</pub-id>\n<pub-id pub-id-type="pmid">26349679</pub-id></mixed-citation>\n      </ref>\n      <ref id="B24">\n        <label>24</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mucci</surname><given-names>LA</given-names></name><name><surname>Hjelmborg</surname><given-names>JB</given-names></name><name><surname>Harris</surname><given-names>JR</given-names></name></person-group>. <article-title>Familial Risk and Heritability of Cancer Among Twins in Nordic Countries (Vol 315, Pg 68, 2016)</article-title>. <source>JAMA-Journal Am Med Assoc</source> (<year>2016</year>) <volume>315</volume>:<page-range>822&#x2013;2</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1001/jama.2016.0197</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B25">\n        <label>25</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AlDubayan</surname><given-names>SH</given-names></name><name><surname>Pyle</surname><given-names>LC</given-names></name><name><surname>Gamulin</surname><given-names>M</given-names></name><name><surname>Kulis</surname><given-names>T</given-names></name><name><surname>Moore</surname><given-names>ND</given-names></name><name><surname>Taylor-Weiner</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors</article-title>. <source>JAMA Oncol</source> (<year>2019</year>) <volume>5</volume>:<page-range>514&#x2013;22</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1001/jamaoncol.2018.6477</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B26">\n        <label>26</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Baron</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>F</given-names></name><name><surname>Barkley</surname><given-names>D</given-names></name><name><surname>Chiodin</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Widespread Transcriptional Scanning in the Testis Modulates Gene Evolution Rates</article-title>. <source>Cell</source> (<year>2020</year>) <volume>180</volume>:<page-range>248&#x2013;+</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.cell.2019.12.015</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B27">\n        <label>27</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Goede</surname><given-names>OM</given-names></name><name><surname>Nachun</surname><given-names>DC</given-names></name><name><surname>Ferraro</surname><given-names>NM</given-names></name><name><surname>Gloudemans</surname><given-names>MJ</given-names></name><name><surname>Rao</surname><given-names>AS</given-names></name><name><surname>Smail</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Population-Scale Tissue Transcriptomics Maps Long Non-Coding RNAs to Complex Disease</article-title>. <source>Cell</source> (<year>2021</year>) <volume>184</volume>:<fpage>2633</fpage>&#x2013;<lpage>+ e19</lpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.cell.2021.03.050</pub-id>\n<pub-id pub-id-type="pmid">33864768</pub-id></mixed-citation>\n      </ref>\n      <ref id="B28">\n        <label>28</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name></person-group>. <article-title>A Stromal and Immune Cell Infiltration-Based Score Model Predicts Prognosis and Chemotherapy Effect in Colorectal Cancer</article-title>. <source>Int Immunopharmacol</source> (<year>2021</year>) <volume>99</volume>:<elocation-id>107940</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.intimp.2021.107940</pub-id>\n<pub-id pub-id-type="pmid">34242996</pub-id></mixed-citation>\n      </ref>\n      <ref id="B29">\n        <label>29</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandya</surname><given-names>PH</given-names></name><name><surname>Murray</surname><given-names>ME</given-names></name><name><surname>Pollok</surname><given-names>KE</given-names></name><name><surname>Renbarger</surname><given-names>JL</given-names></name></person-group>. <article-title>The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches</article-title>. <source>J Immunol Res</source> (<year>2016</year>) <volume>2016</volume>:<elocation-id>4273943</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1155/2016/4273943</pub-id>\n<pub-id pub-id-type="pmid">28116316</pub-id></mixed-citation>\n      </ref>\n      <ref id="B30">\n        <label>30</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siska</surname><given-names>PJ</given-names></name><name><surname>Johnpulle</surname><given-names>RAN</given-names></name><name><surname>Zhou</surname><given-names>A</given-names></name><name><surname>Bordeaux</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Dabbas</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Deep Exploration of the Immune Infiltrate and Outcome Prediction in Testicular Cancer by Quantitative Multiplexed Immunohistochemistry and Gene Expression Profiling</article-title>. <source>Oncoimmunol</source> (<year>2017</year>) <volume>6</volume>:<fpage>e1305535</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1080/2162402x.2017.1305535</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B31">\n        <label>31</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richie</surname><given-names>JP</given-names></name></person-group>. <article-title>Re: CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30(+) and CD30(-) Embryonal Carcinoma <italic>via</italic> Antigen-Dependent and Fas/FasL Interactions</article-title>. <source>J Urol</source> (<year>2020</year>) <volume>203</volume>:<page-range>883&#x2013;4</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1097/ju.0000000000000780</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B32">\n        <label>32</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Long Noncoding RNA PENG Upregulates PDZK1 Expression by Sponging miR-15b to Suppress Clear Cell Renal Cell Carcinoma Cell Proliferation</article-title>. <source>Oncogene</source> (<year>2020</year>) <volume>39</volume>:<page-range>4404&#x2013;20</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/s41388-020-1297-1</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B33">\n        <label>33</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klopfleisch</surname><given-names>R</given-names></name><name><surname>Klose</surname><given-names>P</given-names></name><name><surname>da Costa</surname><given-names>A</given-names></name><name><surname>Brunnberg</surname><given-names>L</given-names></name><name><surname>Gruber</surname><given-names>AD</given-names></name></person-group>. <article-title>HEPACAM1 and 2 Are Differentially Regulated in Canine Mammary Adenomas and Carcinomas and its Lymph Node Metastases</article-title>. <source>BMC Vet Res</source> (<year>2010</year>) <volume>6</volume>:<elocation-id>15</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1186/1746-6148-6-15</pub-id>\n<pub-id pub-id-type="pmid">20226097</pub-id></mixed-citation>\n      </ref>\n      <ref id="B34">\n        <label>34</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Ross</surname><given-names>RK</given-names></name><name><surname>Pike</surname><given-names>MC</given-names></name><name><surname>Casagrande</surname><given-names>JT</given-names></name></person-group>. <article-title>Endogenous Hormones as a Major Factor in Human Cancer</article-title>. <source>Cancer Res</source> (<year>1982</year>) <volume>42</volume>:<page-range>3232&#x2013;9</page-range>.</mixed-citation>\n      </ref>\n      <ref id="B35">\n        <label>35</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byles</surname><given-names>V</given-names></name><name><surname>Covarrubias</surname><given-names>AJ</given-names></name><name><surname>Ben-Sahra</surname><given-names>I</given-names></name><name><surname>Lamming</surname><given-names>DW</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name><name><surname>Manning</surname><given-names>BD</given-names></name><etal/></person-group>. <article-title>The TSC-mTOR Pathway Regulates Macrophage Polarization</article-title>. <source>Nat Commun</source> (<year>2013</year>) <volume>4</volume>:<fpage>2834</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/ncomms3834</pub-id>\n<pub-id pub-id-type="pmid">24280772</pub-id></mixed-citation>\n      </ref>\n      <ref id="B36">\n        <label>36</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fingar</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>CJ</given-names></name><name><surname>Tee</surname><given-names>AR</given-names></name><name><surname>Cheatham</surname><given-names>L</given-names></name><name><surname>Tsou</surname><given-names>C</given-names></name><name><surname>Blenis</surname><given-names>J</given-names></name></person-group>. <article-title>mTOR Controls Cell Cycle Progression Through Its Cell Growth Effectors S6K1 and 4E-BP1/eukaryotic Translation Initiation Factor 4E</article-title>. <source>Mol Cell Biol</source> (<year>2004</year>) <volume>24</volume>:<page-range>200&#x2013;16</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1128/mcb.24.1.200-216.2004</pub-id>\n</mixed-citation>\n      </ref>\n      <ref id="B37">\n        <label>37</label>\n        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weichhart</surname><given-names>T</given-names></name><name><surname>Costantino</surname><given-names>G</given-names></name><name><surname>Poglitsch</surname><given-names>M</given-names></name><name><surname>Rosner</surname><given-names>M</given-names></name><name><surname>Zeyda</surname><given-names>M</given-names></name><name><surname>Stuhlmeier</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response</article-title>. <source>Immunity</source> (<year>2008</year>) <volume>29</volume>:<page-range>565&#x2013;77</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.immuni.2008.08.012</pub-id>\n</mixed-citation>\n      </ref>\n    </ref-list>\n  </back>\n</article>\n</pmc-articleset>'
